Service Revenue was Adaptive Biotechnologies’s largest product and service line in fiscal 2025, bringing in $192.83M of $276.98M (70%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Service Revenue | $112.92M | $102.74M | $133.03M | $192.83M | |||||
| Collaboration Revenue | $66.39M | $42.58M | $13.45M | $41.28M | |||||
| Sequencing Revenue | — | — | — | — | |||||
| Development Support Revenue | — | — | — | — | |||||
| Service & Licensing Revenue | — | $24.96M | $19.98M | $23.36M | |||||
| Development Revenue | — | — | — | — | |||||
| Regulatory Milestone Revenue | $6.00M | — | $12.50M | $19.50M | |||||
| Development Revenue Regulatory Milestones | — | — | — | — | |||||
| Total | $185.31M | $170.28M | $178.96M | $276.98M |
Adaptive Biotechnologies brought in $276.98M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 54.8% from $178.96M in fiscal 2024. Service Revenue was the largest at $192.83M (69.6%), ahead of Collaboration Revenue at $41.28M (14.9%) and Service & Licensing Revenue at $23.36M (8.4%). The remaining line, Regulatory Milestone Revenue, brought in $19.50M.
Compared with fiscal 2024, Collaboration Revenue grew fastest, up 206.9% to $41.28M. Every line above 2% of revenue grew.
Adaptive Biotechnologies began breaking out Service & Licensing Revenue in fiscal 2023, when it brought in $24.96M.
Mrd Revenue was Adaptive Biotechnologies’s largest revenue line in fiscal 2025, bringing in $212.33M of $276.98M (77%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Mrd Revenue | $87.14M | $102.74M | $145.53M | $212.33M | ||
| Immune Medicine Revenue | $98.16M | $67.54M | $33.43M | $64.64M | ||
| Medicare Reimbursements | — | $700.00K | — | — | ||
| Cancelled Customer Contracts | — | $600.00K | — | — | ||
| Total | $185.31M | $171.58M | $178.96M | $276.98M |
Adaptive Biotechnologies brought in $276.98M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 54.8% from $178.96M in fiscal 2024. Mrd Revenue was the largest at $212.33M (76.7%), ahead of Immune Medicine Revenue at $64.64M (23.3%).
Compared with fiscal 2024, Immune Medicine Revenue grew 93.4% to $64.64M and Mrd Revenue grew 45.9% to $212.33M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $185.31M to $276.98M, a compound annual growth rate of 14.3%. Mrd Revenue's share of the total rose from 47.0% to 76.7%.
Adaptive Biotechnologies stopped reporting Medicare Reimbursements ($700.00K in fiscal 2023) and Cancelled Customer Contracts ($600.00K in fiscal 2023) as separate revenue lines.
Mrd was Adaptive Biotechnologies’s largest segment in fiscal 2025, bringing in $212.33M of $276.98M (77%).
| Segment | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Mrd | $87.14M | $102.74M | $145.53M | $212.33M |
| Im | $98.16M | $67.54M | $33.43M | $64.64M |
| Total | $185.31M | $170.28M | $178.96M | $276.98M |
Adaptive Biotechnologies brought in $276.98M from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 54.8% from $178.96M in fiscal 2024. Mrd was the largest at $212.33M (76.7%), ahead of Im at $64.64M (23.3%).
Compared with fiscal 2024, Im grew 93.4% to $64.64M and Mrd grew 45.9% to $212.33M. From fiscal 2022 to 2025, combined revenue from these segments grew from $185.31M to $276.98M, a compound annual growth rate of 14.3%. Mrd's share of the total rose from 47.0% to 76.7%.
Adaptive Biotechnologies (ADPT) reports its revenue by product and service, by collaborative arrangement and arrangement other than collaborative and by segment. In fiscal 2025, Service Revenue was its largest product and service line, bringing in $192.83M (69.6% of the total), followed by Collaboration Revenue at $41.28M (14.9%).
Service Revenue was Adaptive Biotechnologies' largest product and service line in fiscal 2025, bringing in $192.83M, or 69.6% of the $276.98M total across its four product and service lines.
Mrd Revenue was Adaptive Biotechnologies' largest revenue line in fiscal 2025, bringing in $212.33M, or 76.7% of the $276.98M total across its two revenue lines.
Mrd was Adaptive Biotechnologies' largest segment in fiscal 2025, bringing in $212.33M, or 76.7% of the $276.98M total across its two segments.
Among Adaptive Biotechnologies' product and service lines that make up at least 2% of revenue, Collaboration Revenue grew fastest in fiscal 2025, up 206.9% from $13.45M to $41.28M.
Every figure comes from Adaptive Biotechnologies' annual financial filings, as reported. Each line keeps the name Adaptive Biotechnologies gives it, and years follow its fiscal calendar.
Adaptive Biotechnologies' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.